Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Pharmacogenomics and Personalized Medicine is Scopus-indexed (Q2, CiteScore 4.8), WoS SCIE, DOAJ. Published by Dove Medical Press Ltd.
Checked against the index lists dated .
ISSN 1178-7066Verify ISSN ↗
Publisher: Dove Medical Press Ltd
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology | 155 / 328 | 52nd | Q2 |
| Molecular Medicine | 109 / 179 | 39th | Q3 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2009–present, best quartile Q2, CiteScore 4.8.
Pharmacogenomics and Personalized Medicine is Q2 in Pharmacology (rank 155 of 328) and Q3 in Molecular Medicine (rank 109 of 179), by CiteScore 2025.
Pharmacogenomics and Personalized Medicine is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.8, which places it in quartile Q2 at the 52nd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.730, quartile Q2, with an H-index of 44.
The publisher lists an article processing charge of about US$2,836 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Pharmacogenomics and Personalized Medicine is published by Dove Medical Press Ltd. Its ISSN is 1178-7066.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Pharmacogenomics and Personalized Medicine has an h-index of 45 and a 2-year mean of 2.22 citations per paper (OpenAlex). Its Scopus CiteScore is 4.8, quartile Q2. On 2-year citations it ranks #158 of 319 Scopus journals in Pharmacology.
Pharmacogenomics and Personalized Medicine published 23 papers in 2025; its busiest recent year was 2021 with 155. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 91 research articles (2023–2026), authors are most often from China (72.5%), United States (5.3%) and Switzerland (2.9%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (2.8 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.